Daily FNArena News - Australia

A meaty sell off in banks, technology large cap stocks dragged down the ASX200 to its worst performance since April, while gold stocks continued to shine

Fisher & Paykel Healthcare’s first half saw lower costs overcoming a drag from US tariffs. Declining US vaccination rates could provide a boost in the second half

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Shares in TechnologyOne reacted negatively on the release of a record FY25 performance, as not all metrics met elevated expectations and as the global technology sector is de-rated

Today’s EVs are the equivalent of last century’s Model T —a real game-changer— but for investors looking to profit, the challenges are plenty and real

Overviews in raw numbers and calculations that might assist investors with assessing trends and currents that might not be apparent from daily volatility and movements

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Rising demand for commodities testing, supported by the soaring gold price, provided a strong first half for ALS Ltd, and it appears there’s more to come

Digital transformation and AI are forcing companies to increase their spending, but while short-term costs are certain, future benefits are not